Shots: Boston Scientific signs an agreement with Stark International and SERB SAS to sell its BTG specialty pharma business for $800M in cash. The transaction is expected to close in […]readmore
Tags : BTG
Biopharma acquisition activity in 2018 shows a significant increase over the previous year. Takeda proved to be on top with the acquisition of Shire among the top 20 acquisitions with […]readmore
Shots: Boston acquired BTG in all stocks transaction, for ~$1.07/per share at a premium of 36.6%, with total deal value of $4.2B. The transaction is expected to close in H1’19 […]readmore